证券代码：920992 证券简称：中科美菱 公告编号：2025-123 1.基本信息 中科美菱低温科技股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 中科美菱低温科技股份有限公司（以下简称公司）分别于 2025 年 3 月 20 日、2025 年 4 月 11 日召开了第三届董事会第三十四次会议和 2024 年年度股东 大会，审议通过了《关于拟续聘 2025 年度会计师事务所的议案》，同意续聘天健 会计师事务所(特殊普通合伙)作为公司 2025 年度财务报告、内部控制审计机构， 聘任期限一年。具体内容详见公司于 2025 年 3 月 21 日、4 月 11 日在北京证券 交易所网站披露的《拟续聘 2025 年度会计师事务所公告》（公告编号：2025-016）、 《2024 年年度股东大会决议公告》（公告编号：2025-032）。 2025 年 10 月 30 日，公司收到天健会计师事务所(特殊普通合伙)出具的《关 于变更签字注册会计师的函》，现将有关情况公告如 ...

证券代码：920992 证券简称：中科美菱 公告编号：2025-124 中科美菱低温科技股份有限公司 股票解除限售公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、本次股票解除限售数量总额为 19,500,000 股，占公司总股本 20.1590%， 可交易时间为 2025 年 11 月 6 日。 E 公开发行前特定主体股票解除限售 F 参与战略配售取得股票解除限售 G 其他（说明具体原因） | 序号 | 股东姓名或 | 是否为 控股股 东、实 际控制 | | 本次 | 本次解除限 售登记股票 | 本次解除 | 尚未解 除限售 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 任职情 | 解限 | | 限售股数 | | | | 名称 | 人或其 | 况 | 售原 | 数量 | 占公司总 | 的股票 | | | | | | 因 | | 股本比例 | 数量 | | | | 一致行 | | | | | | | | | 动人 | | ...

Investment Rating - The investment rating for the company is "Accumulate" (first coverage) [1][7] Core Viewpoints - The company is a pioneer in the field of ultra-low temperature storage for biological cells in China, backed by Changhong Group and supported by the Chinese Academy of Sciences. It has developed several industry-leading products, including ultra-low temperature storage boxes reaching -180°C, and has a strong patent portfolio with 436 patents as of the end of 2024 [4][7][21]. - The company has shown stable revenue growth, with a projected revenue of 320.91 million yuan in 2025, reflecting an 8.50% increase year-on-year. The net profit is expected to reach 25.22 million yuan, a 39.43% increase [5][7]. - The domestic medical device market is projected to grow significantly, with the market size expected to exceed 1.8 trillion yuan by 2030, and the biological low-temperature storage equipment market is anticipated to grow from 6.772 billion yuan in 2022 to 21.543 billion yuan by 2028 [7][9]. Company Overview - The company, established in 2002, has developed a diverse product portfolio in the ultra-low temperature storage sector, including products that operate in the temperature range of -196°C to 8°C, widely used in medical, research, and biopharmaceutical fields [13][28]. - The company has received numerous accolades, including being recognized as a national-level "specialized and innovative" small giant enterprise and has won various awards for technological innovation [17][21]. Financial Forecast - The financial forecast indicates total revenue of 302.79 million yuan in 2023, with a decline of 25.51%, followed by a slight recovery in 2024 to 295.77 million yuan. The company is expected to achieve a revenue of 320.91 million yuan in 2025, with a growth rate of 8.50% [5][7]. - The projected net profit for 2025 is 25.22 million yuan, representing a significant increase of 39.43% compared to 2024 [5][7]. Industry Analysis - The medical device industry is experiencing rapid growth, driven by various factors, including policy support and increasing demand for domestic medical equipment. The company is well-positioned to benefit from these trends as a leading player in the biological low-temperature storage market [9][28]. - The company has a competitive edge in the market, having ranked among the top three domestic brands in low-temperature storage equipment, and is expected to capture more market share due to its technological advantages [29][40].

Investment Rating - The investment rating for the company is "Accumulate" (首次) [1][9] Core Insights - The company is a pioneer in the field of ultra-low temperature storage for biological cells, breaking foreign monopolies and focusing on technological innovation and market expansion [6][30] - The company has achieved a revenue of 1.5 billion yuan in the first half of 2025, with a year-on-year growth of 2.16%, and a net profit of 11.05 million yuan, reflecting a 5.94% increase [9][31] - The domestic medical device market is projected to reach 1.35 trillion yuan in 2024, with a compound annual growth rate of 7.53% from 2025 to 2030 [9][31] Company Overview - The company, established in 2002, is backed by Changhong Group and supported by the Chinese Academy of Sciences, focusing on ultra-low temperature storage [9][15] - It has received numerous accolades, including being recognized as a national-level "Little Giant" enterprise and winning the National Technology Invention Award [19][23] - The company has a diverse product portfolio, including ultra-low temperature storage boxes and laboratory equipment, with applications in medical, research, and biopharmaceutical fields [30][31] Financial Performance - Revenue projections for 2025-2027 are 320.91 million, 356.79 million, and 406.46 million yuan, with respective growth rates of 8.50%, 11.18%, and 13.92% [7][9] - The net profit for the same period is expected to be 25.22 million, 29.55 million, and 32.70 million yuan, with growth rates of 39.43%, 17.19%, and 10.64% [7][9] - The company's gross margin is reported at 36.67%, with a net margin of 7.35% for the first half of 2025 [9][31] Industry Analysis - The medical device industry is driven by policy and demand, with a significant push for domestic alternatives [11][30] - The market for biological low-temperature storage equipment is expected to grow from 6.772 billion yuan in 2022 to 21.543 billion yuan by 2028 [9][31] - The company is positioned to benefit from increasing demand for medical equipment in rural areas and supportive government policies [9][31] Product and Technology - The company has developed a comprehensive range of products, including ultra-low temperature storage devices and laboratory equipment, covering temperature ranges from -196°C to 8°C [30][31] - It has a strong focus on R&D, with 11.19% of revenue allocated to research, resulting in 436 patents as of the end of 2024 [9][45] - The company aims to enhance its technological capabilities and expand its product offerings in the ultra-low temperature storage sector [42][45]

证券代码：920992 证券简称：中科美菱 公告编号：2025-122 中科美菱低温科技股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、投资者关系活动类别 √特定对象调研 □业绩说明会 参会单位及人员：信达澳银基金、天弘基金管理有限公司、创金合信基金管 理有限公司、高盛工银理财有限责任公司、方正富邦基金管理有限公司、开源证 券股份有限公司、东北证券股份有限公司、民生证券股份有限公司、建信理财有 限责任公司、深圳市国晖投资有限公司、绍兴冰剑投资管理有限公司、上海赛伯 乐投资有限公司、上海睿源私募基金管理有限公司、上海九祥资产管理有限公司、 果实资本、广州市罗爵资产管理有限公司、广东正圆私募基金管理有限公司、点 石成鑫资产管理有限公司、大湾区发展基金管理有限公司、北京星允投资管理有 限公司、北京青创伯乐投资有限公司、涌德瑞烜(上海)私募基金管理有限公司 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 二、投资者关系活动情况 活动时间：2025 ...

Core Insights - The medical device sector experienced a slight increase of 0.37% on October 24, with Mai Lande leading the gains [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Medical Device Sector Performance - Top gainers included: - Mai Lande (688273) with a closing price of 41.92, up 6.31%, trading volume of 29,300 hands, and a transaction value of 121 million yuan [1] - Xiangyu Medical (688626) at 53.21, up 6.10%, with a trading volume of 41,100 hands and a transaction value of 216 million yuan [1] - Xiangsheng Medical (688358) at 35.27, up 4.75%, with a trading volume of 38,400 hands and a transaction value of 136 million yuan [1] - Other notable gainers included: - Aohua Endoscopy (688212) at 50.59, up 4.74%, with a transaction value of 225 million yuan [1] - Weisi Medical (688580) at 49.10, up 4.71%, with a transaction value of approximately 99.8 million yuan [1] Decliners in Medical Device Sector - Notable decliners included: - Chenguang Medical (920300) at 17.51, down 8.80%, with a trading volume of 124,000 hands [2] - Toukeng Life (300642) at 22.95, down 5.40%, with a trading volume of 175,700 hands [2] - Haitai New Light (688677) at 48.50, down 5.05%, with a trading volume of 38,800 hands [2] - Other significant decliners included: - Sino Medical (688108) at 28.00, down 4.73%, with a trading volume of 263,700 hands [2] - Tianchen Medical (688013) at 55.66, down 3.98%, with a trading volume of 19,200 hands [2] Capital Flow in Medical Device Sector - The medical device sector saw a net outflow of 654 million yuan from major funds, while retail investors contributed a net inflow of 455 million yuan [2]

Core Viewpoint - The report indicates that Zhongke Meiling (stock code: 920992) has shown a slight decrease in total assets but an increase in net assets and profitability for the third quarter of 2025 compared to the previous year [3][7]. Financial Data Summary - Total assets as of September 30, 2025, amounted to 727.28 billion, a decrease of 2.41% from 745.28 billion at the end of 2024 [7]. - Net assets attributable to shareholders increased to 618.40 billion, reflecting a growth of 1.09% from 611.74 billion [7]. - The asset-liability ratio for the parent company was 14.18%, down from 16.43%, while the consolidated asset-liability ratio decreased from 17.92% to 14.97% [7]. - Revenue for the first nine months of 2025 reached 224.39 billion, up 4.75% from 214.21 billion in the same period of 2024 [7]. - Net profit attributable to shareholders was 12.76 billion, an increase of 8.19% compared to 11.79 billion [7]. - Basic earnings per share rose to 0.1319 yuan, reflecting an increase of 8.20% from 0.1219 yuan [7]. Cash Flow and Profitability - The net cash flow from operating activities for the first nine months was 3.90 billion, showing a slight decrease of 0.07% from 3.90 billion in the previous year [7]. - The weighted average return on equity based on net profit attributable to shareholders was 2.07%, up from 1.95% [7]. - The weighted average return on equity based on net profit after deducting non-recurring gains and losses increased significantly from 0.44% to 1.06% [7]. Quarterly Performance - For the third quarter of 2025, revenue was 74.16 billion, a growth of 10.44% from 67.15 billion in the same quarter of 2024 [7]. - Net profit attributable to shareholders for the third quarter was 1.71 billion, a substantial increase of 25.42% from 1.36 billion [7]. - The basic earnings per share for the third quarter rose to 0.0177 yuan, an increase of 25.53% from 0.0141 yuan [7]. Major Changes in Financial Data - Cash and cash equivalents decreased by 40.96% to 340.08 billion due to the management of idle funds [9]. - Accounts receivable increased by 223.30% to 9.90 billion, attributed to increased sales during the credit period [9]. - Contract liabilities decreased by 40.10% to 10.89 billion, primarily due to revenue recognition from previous contracts [9]. - Tax payable decreased by 35.80% to 1.66 billion, reflecting a reduction in value-added tax and additional taxes [9]. Shareholder Structure - The total number of ordinary shares at the end of the reporting period was 96.73 billion, with 5,496 shareholders [12]. - The largest shareholder, Changhong Meiling Co., Ltd., holds 45.90 billion shares, representing 47.45% of the total [12]. - The second-largest shareholder, Zhongke Xianxing (Beijing) Asset Management Co., Ltd., holds 19.50 billion shares, accounting for 20.16% [12].

证券代码：920992 证券简称：中科美菱 公告编号：2025-120 中科美菱低温科技股份有限公司 第四届董事会第六次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 10 月 22 日 2.会议召开地点：公司会议室 6.会议列席人员：公司董事会秘书及其他高级管理人员 7.召开情况合法合规的说明： 本次会议的召集、召开、议案审议程序等符合有关法律、行政法规、部门 规章、规范性文件和《公司章程》的有关规定。 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 二、议案审议情况 （一）审议通过《2025 年第三季度报告》 1.议案内容： 3.会议召开方式：通讯方式 4.发出董事会会议通知的时间和方式：2025 年 10 月 20 日以电子邮件方式发 出 5.会议主持人：董事长吴定刚先生 根据公司业务发展以及经营管理的需要，同意公司向中国民生银行股份有 限公司合肥分行申请 3000 万元人民币最高授 ...

中科美菱低温科技股份有限公司 目 录 章 程 二〇二五年十月 （经公司2025年10月15日召开的2025年第二次临时股东会审议通过） 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第三节 股份转让 第五章 董事会 第四章 股东和股东会 第四节 董事会专门委员会 第六章 公司党组织 第七章 总经理及其他高级管理人员 第八章 财务会计制度、利润分配和审计 第九章 通知和公告 第一节 股份发行 第二节 股份增减和回购 第一节 股东 第二节 股东会的一般规定 第三节 股东会的召集 第四节 股东会的提案与通知 第五节 股东会的召开 第六节 股东会的表决和决议 第二节 解散和清算 第十一章 投资者关系管理 第十二章 修改章程 第十三章 附则 第一章 总则 第一条 为深入贯彻习近平新时代中国特色社会主义思想，规范中科美菱低 温科技股份有限公司（以下简称"公司"）的组织和行为，全面贯彻落实"两个 一以贯之"重要要求，坚持和加强党的全面领导，完善公司法人治理结构，建设 中国特色现代企业制度，维护公司、股东、职工、债权人的合法权益，依据《中 华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国企业国有资 产法》《 ...

证券代码：920992 证券简称：中科美菱 公告编号：2025-118 中科美菱低温科技股份有限公司 2025 年第二次临时股东会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 10 月 15 日 2.会议召开地点：安徽省合肥市经济技术开发区紫石路 1862 号公司会议室 3.会议召开方式：现场投票和网络投票相结合的方式 4.会议召集人：董事长 5.会议主持人：董事长吴定刚先生 6.召开情况合法合规的说明： 本次股东会的召开符合《公司法》等有关法律、法规及《公司章程》的规 定。 （二）会议出席情况 出席和授权出席本次股东会的股东共 6 人，持有表决权的股份总数 67,637,155 股，占公司有表决权股份总数的 69.9230%。 其中通过网络投票参与本次股东会的股东共 0 人，持有表决权的股份总数 0 股，占公司有表决权股份总数的 0%。 （三）公司董事、监事、高级管理人员出席或列席股东会情况 1.公司在任董事 7 ...